Contact
Please use this form to send email to PR contact of this press release:
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
TO: